Literature DB >> 16364567

Pharmacological content of tablets sold as "ecstasy": results from an online testing service.

Emily E Tanner-Smith1.   

Abstract

PURPOSE: This study examined the pharmacological content of tablets sold as ecstasy, the variation of tablet content by geographic region, and change in tablet content between 1999 and 2005.
METHODS: The sample was comprised of tablets anonymously submitted for laboratory testing between 1999 and 2005 (n=1214). Tablet height, width, geographic region, and year of submission were all used to predict the pharmacological content of the tablets.
RESULTS: Overall, 39% of the tablets were comprised of MDMA only, 46% only contained substances other than MDMA and 15% were mixtures of MDMA and other substances. Tablet height and width were inversely related to tablet purity. Ecstasy tablets from California and Florida had decreased likelihoods of containing non-MDMA substances. The purity of tablets decreased over time, which was largely a result of an increasing number of tablets comprised of MDMA along with other substances.
CONCLUSIONS: Ecstasy users may be putting themselves at increased risk of substance-induced anxiety, mood, and psychotic disorders by unknowingly ingesting substances other than MDMA. To decrease detrimental health effects, prevention programs should emphasize the impurity of ecstasy tablets and focus on the health impacts of these substances, particularly for populations at high-risk of substance-induced disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364567     DOI: 10.1016/j.drugalcdep.2005.11.016

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

1.  Prevalence of reagent test-kit use and perceptions of purity among ecstasy users in an electronic dance music scene in New York City.

Authors:  Joseph J Palamar; Monica J Barratt
Journal:  Drug Alcohol Rev       Date:  2018-12-21

Review 2.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

3.  Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

Authors:  R D Crean; S A Davis; S N Von Huben; C C Lay; S N Katner; M A Taffe
Journal:  Neuroscience       Date:  2006-07-28       Impact factor: 3.590

4.  Illicit drug use among rave attendees in a nationally representative sample of US high school seniors.

Authors:  Joseph J Palamar; Marybec Griffin-Tomas; Danielle C Ompad
Journal:  Drug Alcohol Depend       Date:  2015-05-13       Impact factor: 4.492

5.  There's something about Molly: The underresearched yet popular powder form of ecstasy in the United States.

Authors:  Joseph J Palamar
Journal:  Subst Abus       Date:  2016-12-07       Impact factor: 3.716

6.  Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.

Authors:  John H Halpern; Andrea R Sherwood; James I Hudson; Staci Gruber; David Kozin; Harrison G Pope
Journal:  Addiction       Date:  2011-02-15       Impact factor: 6.526

7.  Self-Reported Ecstasy/MDMA/"Molly" Use in a Sample of Nightclub and Dance Festival Attendees in New York City.

Authors:  Joseph J Palamar; Patricia Acosta; Danielle C Ompad; Charles M Cleland
Journal:  Subst Use Misuse       Date:  2016-09-23       Impact factor: 2.164

8.  Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques.

Authors:  Rebecca D Crean; Sophia A Davis; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2007-04-03       Impact factor: 3.533

9.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.